ProtoKinetix (PKTX) 10-K 30 Apr 14 2012 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2012	Apr. 28, 2014	Jun. 30, 2012
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-12	'	'
Trading Symbol	'pktx	'	'
Entity Registrant Name	'ProtoKinetix, Inc.	'	'
Entity Central Index Key	'0001128189	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	170,362,433	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Well Known Seasoned Issuer	'No	'	'
Entity Public Float	'	'	$1,320,000
Document Fiscal Year Focus	'2012	'	'
Document Fiscal Period Focus	'FY	'	'

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2012	Dec. 31, 2011
Current Assets	'	'
Cash	$2,406	$4,512
Prepaid expenses	0	18,731
Accounts receivable	6,020	6,528
Total current assets and total assets	8,426	29,771
Current Liabilities	'	'
Accounts payable and accrued liabilities	181,399	153,391
Short-term loan	34,500	36,735
Convertible note payable	300,000	300,000
Total current liabilities	515,899	490,126
Stockholders' Deficit	'	'
Common stock, $0.0000053 par value; 200,000,000 common shares authorized; 134,512,433 and 119,512,433 shares issued and outstanding for 2012 and 2011 respectively	722	643
Share subscription received in advance	25,000	25,000
Additional paid-in capital	24,690,587	24,540,666
Deficit accumulated during the development stage	-25,223,782	-25,026,664
Total stockholders' deficit	-507,473	-460,355
Total liabilities and stockholders' deficit	$8,426	$29,771

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	134,512,433	119,512,433
Common Stock, Shares, Outstanding	134,512,433	119,512,433

STATEMENT_OF_OPERATIONS

STATEMENT OF OPERATIONS (USD $)	12 Months Ended		156 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Revenues	$0	$0	$2,000
Expenses	'	'	'
Licenses	0	0	3,379,756
Professional fees	34,988	74,497	3,578,463
Consulting fees	18,731	512,032	13,365,513
Research and development	0	117,415	2,657,591
General and administrative	119,399	200,989	1,726,471
Interest	24,000	12,000	168,162
Total Operating Expenses	197,118	916,933	24,875,956
Loss from continuing operations	-197,118	-916,933	-24,873,956
Other Income (Expense)	0	15,000	15,000
Write-off of accounts payable	0	0	8,640
Loss on debt conversion	0	-330,000	-330,000
Loss before discontinued operations	-197,118	-1,231,933	-25,180,316
Loss from operations of the discontinued segment	0	0	-43,466
Net loss for the period	($197,118)	($1,231,933)	($25,223,782)
Net Loss per Common Share (basic and diluted)	$0	($0.01)	'
Weighted average number of common shares outstanding (basic and diluted)	129,224,762	93,592,433	'

STATEMENTS_OF_STOCKHOLDERS_EQU

STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) (USD $)	Common Stock [Member]	Shares Committed For Issuance [Member]	Additional Paid-In Capital [Member]	Stock Subscriptions Received in Advance (Receivable) [Member]	Deficit Accumulated During the Development Stage [Member]	Total
Beginning Balance at Dec. 31, 1999	$50	'	$4,950	'	'	$5,000
Beginning Balance (Shares) at Dec. 31, 1999	9,375,000	'	'	'	'	'
Net Income (Loss)	'	'	'	'	-35	-35
Ending Balance at Dec. 31, 2000	50	'	4,950	'	-35	4,965
Beginning Balance (Shares) at Dec. 31, 2000	9,375,000	'	'	'	'	'
Issuance of common stock, April 2001	30	'	15,220	'	'	15,250
Issuance of common stock, April 2001 (Shares)	5,718,750	'	'	'	'	'
Net Income (Loss)	'	'	'	'	-16,902	-16,902
Ending Balance at Dec. 31, 2001	80	'	20,170	'	-16,937	3,313
Ending Balance (Shares) at Dec. 31, 2001	15,093,750	'	'	'	'	'
Net Income (Loss)	'	'	'	'	-14,878	-14,878
Ending Balance at Dec. 31, 2002	80	'	20,170	'	-31,815	-11,565
Beginning Balance (Shares) at Dec. 31, 2002	15,093,750	'	'	'	'	'
Issuance Of Common Stock For Services July 2003	11	'	424,989	'	'	425,000
Issuance Of Common Stock For Services July 2003 (Shares)	2,125,000	'	'	'	'	'
Issuance Of Common Stock For Services August 2003	2	'	14,998	'	'	15,000
Issuance Of Common Stock For Services August 2003 (Shares)	300,000	'	'	'	'	'
Issuance Of Common Stock For Services September 2003	5	'	49,995	'	'	50,000
Issuance Of Common Stock For Services September 2003 (Shares)	1,000,000	'	'	'	'	'
Issuance Of Common Stock For Services October 2003	8	'	619,992	'	'	620,000
Issuance Of Common Stock For Services October 2003 (Shares)	1,550,000	'	'	'	'	'
Issuance of common stock for licensing rights	74	'	2,099,926	'	'	2,100,000
Issuance of common stock for licensing rights (Shares)	14,000,000	'	'	'	'	'
Common stock issuable for licensing rights	'	11	299,989	'	'	300,000
Common stock issuable for licensing rights (Shares)	'	2,000,000	'	'	'	'
Shares cancelled on September 30, 2003	-49	'	49	'	'	'
Shares cancelled on September 30, 2003 (Shares)	-9,325,000	'	'	'	'	'
Net Income (Loss)	'	'	'	'	-3,662,745	-3,662,745
Ending Balance at Dec. 31, 2003	131	11	3,530,108	'	-3,694,560	-164,310
Ending Balance (Shares) at Dec. 31, 2003	24,743,750	2,000,000	'	'	'	'
Issuance of common stock for services March 2004	9	'	991,371	'	'	991,380
Issuance of common stock for services March 2004 (Shares)	1,652,300	'	'	'	'	'
Issuance of common stock for services May 2004	3	'	514,997	'	'	515,000
Issuance of common stock for services May 2004 (Shares)	500,000	'	'	'	'	'
Issuance of common stock for services July 2004	1	'	119,694	'	'	119,695
Issuance of common stock for services July 2004 (Shares)	159,756	'	'	'	'	'
Issuance of common stock for services August 2004	1	'	70,999	'	'	71,000
Issuance of common stock for services August 2004 (Shares)	100,000	'	'	'	'	'
Issuance of common stock for services October 2004	4	'	479,996	'	'	480,000
Issuance of common stock for services October 2004 (Shares)	732,400	'	'	'	'	'
Issuance of common stock for services November 2004	4	'	454,996	'	'	455,000
Issuance of common stock for services November 2004 (Shares)	650,000	'	'	'	'	'
Issuance of common stock for services December 2004	1	'	164,425	'	'	164,426
Issuance of common stock for services December 2004 (Shares)	255,000	'	'	'	'	'
Common stock issuable for AFGP license	'	5	709,995	'	'	710,000
Common stock issuable for AFGP license (Shares)	'	1,000,000	'	'	'	'
Common stock issuable for Recaf License	'	2	223,998	'	'	224,000
Common stock issuable for Recaf License (Shares)	'	400,000	'	'	'	'
Warrants granted (for 3,450,000 shares) for services, October 2004	'	'	1,716,253	'	'	1,716,253
Options granted for services, October 2004	'	'	212,734	'	'	212,734
Stock subscriptions receivable	'	10	329,990	-330,000	'	'
Stock subscriptions receivable (Shares)	'	1,800,000	'	'	'	'
Warrants exercised August 2004	'	'	15,000	'	'	15,000
Warrants exercised August 2004 (Shares)	'	50,000	'	'	'	'
Warrants exercised October 2004	'	3	134,997	'	'	135,000
Warrants exercised October 2004 (Shares)	'	600,000	'	'	'	'
Warrants exercised December 2004	'	5	224,995	'	'	225,000
Warrants exercised December 2004 (Shares)	'	1,000,000	'	'	'	'
Options exercised, December 2004	'	1	29,999	'	'	30,000
Options exercised, December 2004 (Shares)	'	100,000	'	'	'	'
Net Income (Loss)	'	'	'	'	-6,368,030	-6,368,030
Ending Balance at Dec. 31, 2004	154	37	9,924,547	-330,000	-10,062,590	-467,852
Ending Balance (Shares) at Dec. 31, 2004	28,793,206	6,950,000	'	'	'	'
Issuance of common stock for licensing rights	11	-11	'	'	'	'
Issuance of common stock for licensing rights (Shares)	2,000,000	-2,000,000	'	'	'	'
Issuance of stock subscriptions receivable	'	'	'	240,000	'	240,000
Issuance of stock for warrants exercised	10	-10	'	'	'	'
Issuance of stock for warrants exercised (Shares)	2,050,000	-2,050,000	'	'	'	'
Options exercised February 2005	'	1	10,499	'	'	10,500
Options exercised February 2005 (Shares)	'	35,000	'	'	'	'
Options exercised May 2005	1	'	59,999	'	'	60,000
Options exercised May 2005 (Shares)	200,000	'	'	'	'	'
Note payable conversion, February 2005	'	1	85,749	'	'	85,750
Note payable conversion, February 2005 (Shares)	'	285,832	'	'	'	'
Issuance of common stock for Note payable conversion April 2005	1	-1	'	'	'	'
Issuance of common stock for Note payable conversion April 2005 (Shares)	285,832	-285,832	'	'	'	'
Issuance of common stock for Note payable conversion May 2005	2	'	105,925	'	'	105,927
Issuance of common stock for Note payable conversion May 2005 (Shares)	353,090	'	'	'	'	'
Issuance of common stock for AFGP license	5	-5	'	'	'	'
Issuance of common stock for AFGP license (Shares)	1,000,000	-1,000,000	'	'	'	'
Issuance of common stock for stock subscriptions received	6	-6	'	90,000	'	90,000
Issuance of common stock for stock subscriptions received (Shares)	1,400,000	-1,400,000	'	'	'	'
Issuance of stock for options exercised	2	-2	'	'	'	'
Issuance of stock for options exercised (Shares)	135,000	-135,000	'	'	'	'
Issuance of common stock for services April 2005	1	'	14,999	'	'	15,000
Issuance of common stock for services April 2005 (Shares)	30,000	'	'	'	'	'
Issuance of common stock for services May 2005	15	'	3,320,985	'	'	3,321,000
Issuance of common stock for services May 2005 (Shares)	3,075,000	'	'	'	'	'
Issuance of common stock for services June 2005	1	'	50,499	'	'	50,500
Issuance of common stock for services June 2005 (Shares)	50,000	'	'	'	'	'
Issuance of common stock for services August 2005	1	-1	15,000	'	'	15,000
Issuance of common stock for services August 2005 (Shares)	-250,000	-92,593	'	'	'	'
Issuance of common stock for services August 2005	-1	'	-257,499	'	'	-257,500
Issuance of common stock for services August 2005 (Shares)	111,111	'	'	'	'	'
Issuance of common stock for services October 2005	1	-1	'	'	'	'
Issuance of common stock for services October 2005 (Shares)	36,233	-36,233	'	'	'	'
Issuance of common stock for services November 2005	2	-1	36,249	'	'	36,250
Issuance of common stock for services November 2005 (Shares)	311,725	-245,000	'	'	'	'
Issuance of common stock for services December 2005	8	'	756,392	'	'	756,400
Issuance of common stock for services December 2005 (Shares)	1,220,000	'	'	'	'	'
Common stock issuable for services rendered June 2005	'	1	149,999	'	'	150,000
Common stock issuable for services rendered June 2005 (Shares)	'	200,000	'	'	'	'
Common stock issuable for services rendered August 2005	'	1	21,739	'	'	21,740
Common stock issuable for services rendered August 2005 (Shares)	'	36,233	'	'	'	'
Common stock issuable for services rendered September 2005	'	1	74,999	'	'	75,000
Common stock issuable for services rendered September 2005 (Shares)	'	125,000	'	'	'	'
Common stock issuable for services rendered September 2005 (Proteocell)	'	1	57,999	'	'	58,000
Common stock issuable for services rendered September 2005 (Proteocell) (Shares)	'	100,000	'	'	'	'
Common stock issuable for services rendered December 2005	'	1	74,999	'	'	75,000
Common stock issuable for services rendered December 2005 (Shares)	'	120,968	'	'	'	'
Net Income (Loss)	'	'	'	'	-4,826,540	-4,826,540
Ending Balance at Dec. 31, 2005	220	6	14,503,079	'	-14,889,130	-385,825
Ending Balance (Shares) at Dec. 31, 2005	40,801,197	608,375	'	'	'	'
February 2006 private placement (issued June 2006)	5	'	352,142	'	'	352,147
February 2006 private placement (issued June 2006) (Shares)	900,000	'	'	'	'	'
Warrants granted from private placement (450,000)	'	'	97,853	'	'	97,853
Issuance of common stock for Note payable conversion	3	'	158,780	'	'	158,783
Issuance of common stock for Note payable conversion (Shares)	529,279	'	'	'	'	'
Issuance of common stock for services February March 2006 services	'	1	10,499	'	'	10,500
Issuance of common stock for services February March 2006 services (Shares)	166,359	20,000	'	'	'	'
Issuance of common stock for services March 2006	1	-1	36,750	'	'	36,750
Issuance of common stock for services March 2006 (Shares)	'	-108,375	'	'	'	'
Issuance of common stock for services April 2006	-6	'	6	'	'	'
Issuance of common stock for services April 2006 (Shares)	-1,200,000	'	'	'	'	'
Issuance of common stock for services May 2006	7	-1	792,750	'	'	792,756
Issuance of common stock for services May 2006 (Shares)	1,266,278	-70,000	'	'	'	'
Issuance of common stock for services June 2006	'	6	718,244	'	'	718,250
Issuance of common stock for services June 2006 (Shares)	27,056	1,200,000	'	'	'	'
Issuance of common stock for services July 2006	6	-6	'	'	'	'
Issuance of common stock for services July 2006 (Shares)	1,200,000	-1,200,000	'	'	'	'
Issuance of common stock for services August 2006	1	'	64,999	'	'	65,000
Issuance of common stock for services August 2006 (Shares)	100,000	'	'	'	'	'
Issuance of common stock for services September 2006	2	'	209,998	'	'	210,000
Issuance of common stock for services September 2006 (Shares)	369,984	-50,000	'	'	'	'
Issuance of common stock for services November 2006	1	'	48,999	'	'	49,000
Issuance of common stock for services November 2006 (Shares)	100,000	'	'	'	'	'
Issuance of common stock for services December 2006	'	'	3,010	'	'	3,010
Issuance of common stock for services December 2006 (Shares)	7,000	'	'	'	'	'
Warrants issued (for 700,000 shares) for services	'	'	58,658	'	'	58,658
Net Income (Loss)	'	'	'	'	-1,967,633	-1,967,633
Ending Balance at Dec. 31, 2006	240	5	17,055,767	'	-16,856,763	199,249
Ending Balance (Shares) at Dec. 31, 2006	44,267,153	400,000	'	'	'	'
Issuance of common stock for services January 2007	1	'	119,999	'	'	120,000
Issuance of common stock for services January 2007 (Shares)	218,834	'	'	'	'	'
Issuance of common stock for services March 2007	1	'	44,999	'	'	45,000
Issuance of common stock for services March 2007 (Shares)	104,652	'	'	'	'	'
Issuance of common stock for services April 2007	1	'	74,999	'	'	75,000
Issuance of common stock for services April 2007 (Shares)	187,500	'	'	'	'	'
Issuance of common stock for services June 2007	1	'	44,999	'	'	45,000
Issuance of common stock for services June 2007 (Shares)	112,500	'	'	'	'	'
Issuance of common stock for services July 2007	2	'	112,998	'	'	113,000
Issuance of common stock for services July 2007 (Shares)	291,812	'	'	'	'	'
Issuance of common stock for services August 2007	5	'	257,995	'	'	258,000
Issuance of common stock for services August 2007 (Shares)	860,000	'	'	'	'	'
Issuance of common stock for services September 2007	8	'	457,492	'	'	457,500
Issuance of common stock for services September 2007 (Shares)	1,516,275	'	'	'	'	'
Issuance of common stock for services October 2007	1	'	37,499	'	'	37,500
Issuance of common stock for services October 2007 (Shares)	250,000	'	'	'	'	'
Issuance of common stock for services December 2007	1	'	74,999	'	'	75,000
Issuance of common stock for services December 2007 (Shares)	535,716	'	'	'	'	'
Warrants issued for services	'	'	825,476	'	'	825,476
Cancellation of issuable stock for Recaf License	'	-5	'	'	'	-5
Cancellation of issuable stock for Recaf License (Shares)	'	-400,000	'	'	'	'
Warrants exercised December 2007	1	'	43,999	'	'	44,000
Warrants exercised December 2007 (Shares)	100,000	'	'	'	'	'
Issuable common stock from Private Placement	'	6	172,494	'	'	172,500
Issuable common stock from Private Placement (Shares)	'	1,190,000	'	'	'	'
Net Income (Loss)	'	'	'	'	-2,728,269	-2,728,269
Ending Balance at Dec. 31, 2007	262	6	19,323,715	'	-19,585,032	-261,049
Ending Balance (Shares) at Dec. 31, 2007	48,444,442	1,190,000	'	'	'	'
Issuance of common stock for services March 2008	2	'	133,867	'	'	133,869
Issuance of common stock for services March 2008 (Shares)	369,346	'	'	'	'	'
Issuance of common stock for services May 2008	2	'	137,723	'	'	137,725
Issuance of common stock for services May 2008 (Shares)	395,170	'	'	'	'	'
Issuance of common stock for services July 2008	13	'	577,226	'	'	577,239
Issuance of common stock for services July 2008 (Shares)	2,405,170	'	'	'	'	'
Issuance of common stock for services September 2008	1	'	42,878	'	'	42,879
Issuance of common stock for services September 2008 (Shares)	186,430	'	'	'	'	'
Issuance of common stock for services October 2008	1	'	49,999	'	'	50,000
Issuance of common stock for services October 2008 (Shares)	250,000	'	'	'	'	'
Issuance of common stock for services November 2008	5	'	153,495	'	'	153,500
Issuance of common stock for services November 2008 (Shares)	1,018,375	'	'	'	'	'
Issuance of common stock for proceeds of $50,000 received in 2007	1	'	-1	'	'	'
Issuance of common stock for proceeds of $50,000 received in 2007 (Shares)	173,000	'	'	'	'	'
Stock-based compensation expense related to non-employee stock options	'	'	82,214	'	'	82,214
Warrants exercised September 2008	1	'	25,499	'	'	25,500
Warrants exercised September 2008 (Shares)	170,000	'	'	'	'	'
Warrants exercised November 2008	1	'	12,313	'	'	12,314
Warrants exercised November 2008 (Shares)	100,000	'	'	'	'	'
Warrants exercised December 2008	1	'	25,499	'	'	25,500
Warrants exercised December 2008 (Shares)	170,000	'	'	'	'	'
Issuance of common stock from Private Placement	18	-6	337,488	'	'	337,500
Issuance of common stock from Private Placement (Shares)	3,400,000	-1,190,000	'	'	'	'
Issuable common stock to Directors	'	3	95,997	'	'	96,000
Issuable common stock to Directors (Shares)	'	600,000	'	'	'	'
Net Income (Loss)	'	'	'	'	-1,550,818	-1,550,818
Ending Balance at Dec. 31, 2008	308	3	20,997,912	'	-21,135,850	-137,627
Ending Balance (Shares) at Dec. 31, 2008	57,081,933	600,000	'	'	'	'
Issuance of common stock from Private Placement	4	'	74,996	'	'	75,000
Issuance of common stock from Private Placement (Shares)	750,000	'	'	'	'	'
Issuable common stock to Directors	9	-3	124,994	'	'	125,000
Issuable common stock to Directors (Shares)	1,850,000	-600,000	'	'	'	'
Issuance of common stock for services April 2009	6	'	134,680	'	'	134,686
Issuance of common stock for services April 2009 (Shares)	1,200,000	'	'	'	'	'
Issuance of common stock for services May 2009	3	'	49,997	'	'	50,000
Issuance of common stock for services May 2009 (Shares)	500,000	'	'	'	'	'
Issuance of common stock for services June 2009	3	'	26,997	'	'	27,000
Issuance of common stock for services June 2009 (Shares)	300,000	'	'	'	'	'
Issuance of common stock for services July 2009	8	'	235,402	'	'	235,410
Issuance of common stock for services July 2009 (Shares)	1,324,500	'	'	'	'	'
Issuance of common stock for services October 2009	27	'	379,973	'	'	380,000
Issuance of common stock for services October 2009 (Shares)	5,050,000	'	'	'	'	'
Issuance of common stock for services December 2009	4	'	60,476	'	'	60,480
Issuance of common stock for services December 2009 (Shares)	756,000	'	'	'	'	'
Stock subscription received in advance	'	'	'	71,250	'	71,250
Net Income (Loss)	'	'	'	'	-1,270,109	-1,270,109
Ending Balance at Dec. 31, 2009	372	'	22,085,427	71,250	-22,405,959	-248,910
Ending Balance (Shares) at Dec. 31, 2009	68,812,433	'	'	'	'	'
Issuable common stock to Directors	6	'	94,494	'	'	94,500
Issuable common stock to Directors (Shares)	1,350,000	'	'	'	'	'
Stock subscription received in advance	'	'	'	50,000	'	50,000
Issuance of common stock for services January 2010	6	'	98,544	'	'	98,550
Issuance of common stock for services January 2010 (Shares)	1,095,000	'	'	'	'	'
Issuance of common stock for services March 2010	5	'	47,995	'	'	48,000
Issuance of common stock for services March 2010 (Shares)	600,000	'	'	'	'	'
Issuance of common stock for services April 2010	1	'	22,499	'	'	22,500
Issuance of common stock for services April 2010 (Shares)	250,000	'	'	'	'	'
Issuance of common stock for services May 2010	5	'	82,975	'	'	82,980
Issuance of common stock for services May 2010 (Shares)	922,000	'	'	'	'	'
Issuance of common stock for services June 2010	1	'	21,999	'	'	22,000
Issuance of common stock for services June 2010 (Shares)	200,000	'	'	'	'	'
Issuance of common stock for services July 2010	4	'	82,996	'	'	83,000
Issuance of common stock for services July 2010 (Shares)	850,000	'	'	'	'	'
Issuance of common stock for services August 2010	2	'	23,998	'	'	24,000
Issuance of common stock for services August 2010 (Shares)	300,000	'	'	'	'	'
Issuance of common stock for services September 2010	34	'	437,466	'	'	437,500
Issuance of common stock for services September 2010 (Shares)	6,250,000	'	'	'	'	'
Issuance of common stock for services October 2010	1	'	17,499	'	'	17,500
Issuance of common stock for services October 2010 (Shares)	250,000	'	'	'	'	'
Issuance of common stock for services December 2010	3	'	34,977	'	'	34,980
Issuance of common stock for services December 2010 (Shares)	583,000	'	'	'	'	'
Issuance of common stock from Private Placement January 2010	7	'	124,993	-71,250	'	53,750
Issuance of common stock from Private Placement January 2010 (Shares)	1,250,000	'	'	'	'	'
Issuance of common stock from Private Placement September 2010	4	'	74,996	'	'	75,000
Issuance of common stock from Private Placement September 2010 (Shares)	750,000	'	'	'	'	'
Issuance of common stock to settle short term loan September 2010	1	'	24,999	'	'	25,000
Issuance of common stock to settle short term loan September 2010 (Shares)	250,000	'	'	'	'	'
Net Income (Loss)	'	'	'	'	-1,388,772	-1,388,772
Ending Balance at Dec. 31, 2010	452	'	23,275,857	50,000	-23,794,731	-468,422
Ending Balance (Shares) at Dec. 31, 2010	83,712,433	'	'	'	'	'
Issuable common stock from Private Placement (Shares)	'	'	'	'	'	750,000
Issuance of common stock from Private Placement	3	'	74,997	-75,000	'	'
Issuance of common stock from Private Placement (Shares)	750,000	'	'	'	'	'
Issuable common stock to Directors	17	'	67,983	'	'	68,000
Issuable common stock to Directors (Shares)	3,400,000	'	'	'	'	'
Issuance of common stock to settle convertible debt	48	'	629,952	'	'	630,000
Issuance of common stock to settle convertible debt (Shares)	9,000,000	'	'	'	'	9,000,000
Stock subscription received in advance	'	'	'	50,000	'	50,000
Issuance of common stock for services March 2011	3	'	32,997	'	'	33,000
Issuance of common stock for services March 2011 (Shares)	550,000	'	'	'	'	'
Issuance of common stock for services June 2011	1	'	7,499	'	'	7,500
Issuance of common stock for services June 2011 (Shares)	250,000	'	'	'	'	'
Issuance of common stock for services July 2011	1	'	5,999	'	'	6,000
Issuance of common stock for services July 2011 (Shares)	200,000	'	'	'	'	'
Issuance of common stock for services September 2011	3	'	22,497	'	'	22,500
Issuance of common stock for services September 2011 (Shares)	750,000	'	'	'	'	'
Issuance of common stock for services October 2011	2	'	14,998	'	'	15,000
Issuance of common stock for services October 2011 (Shares)	500,000	'	'	'	'	'
Issuance of common stock for services December 2011	113	'	407,887	'	'	408,000
Issuance of common stock for services December 2011 (Shares)	20,400,000	'	'	'	'	'
Net Income (Loss)	'	'	'	'	-1,231,933	-1,231,933
Ending Balance at Dec. 31, 2011	643	'	24,540,666	25,000	-25,026,664	-460,355
Ending Balance (Shares) at Dec. 31, 2011	119,512,433	'	'	'	'	'
Issuance of common stock from Private Placement	79	'	149,921	'	'	150,000
Issuance of common stock from Private Placement (Shares)	15,000,000	'	'	'	'	15,000,000
Net Income (Loss)	'	'	'	'	-197,118	-197,118
Ending Balance at Dec. 31, 2012	$722	'	$24,690,587	$25,000	($25,223,782)	($507,473)
Ending Balance (Shares) at Dec. 31, 2012	134,512,433	'	'	'	'	'

STATEMENT_OF_CASH_FLOWS

STATEMENT OF CASH FLOWS (USD $)	12 Months Ended		156 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Cash Flows from Operating Activities	'	'	'
Net loss for period	($197,118)	($1,231,933)	($25,223,782)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation expense	0	0	3,388
Write-off of accounts payable	0	0	-8,640
Loss on settlement of debt	0	330,000	330,000
Issuance and amortization of common stock for services	0	596,032	18,727,204
Issuance and amortization of warrants for services	0	0	2,629,730
Issuance and amortization of stock options for services	0	0	222,817
Changes in operating assets and liabilities	'	'	'
Accounts receivable	508	-6,528	-6,020
Prepaid expenses	18,731	0	63,494
Accounts payable and accrued liabilities	28,008	-84,206	190,039
Net cash used in operating activities	-149,871	-396,635	-3,071,770
Cash Flows from Investing Activities	'	'	'
Purchase of computer equipment	0	0	-3,388
Net cash used in investing activities	0	0	-3,388
Cash Flows from Financing Activities	'	'	'
Short-term loan	22,765	36,735	34,500
Warrants exercised	0	0	812,314
Stock options exercised	0	0	100,500
Issuance of common stock for cash	125,000	50,000	1,505,250
Share subscription received in advance	0	0	25,000
Loan proceeds	0	300,000	600,000
Net cash provided financing activities	147,765	386,735	3,077,564
Net change in cash	-2,106	-9,900	2,406
Cash, beginning of period	4,512	14,412	0
Cash, end of period	2,406	4,512	2,406
Cash paid for interest	0	0	50,222
Cash paid for income taxes	0	0	0
Supplementary information - Non-cash Transactions:	'	'	'
Note payable converted to common stock	0	0	350,457
Common stock issued for prepaid consulting services	0	18,731	18,731
Shares issued to settle debts	25,000	0	25,000
Common stock issued to settle convertible debt	$0	$300,000	$300,000

Basis_of_Presentation_Going_Co

Basis of Presentation Going Concern Uncertainties	12 Months Ended
	Dec. 31, 2012
Basis of Presentation Going Concern Uncertainties [Text Block]	'
	Note 1. Basis of Presentation – Going Concern Uncertainties
	ProtoKinetix, Incorporated (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care.
	In 2003, the Company entered into an assignment of license agreement (the "Agreement") with BioKinetix, Inc., an Alberta, Canada, corporation. The Agreement provided the Company with an exclusive assignment of all of the rights (the "Rights") that BioKinetix possessed relating to proprietary technologies that are being developed for the creation and commercialization of "superantibodies," an enhancement of antibody technology that makes ordinary antibodies much more lethal. In consideration, the Company's Board of Directors authorized the Company to issue 16,000,000 shares of its common stock to the shareholders of BioKinetix.
	The Company is also currently researching the benefits and feasibility of proprietary synthesized Antifreeze Glycoproteins ("AFGP"). In preliminary studies, AFGP has demonstrated an ability to protect and preserve human cells at temperatures below freezing.
	The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.
	As shown in the financial statements, the Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at December 31, 2012. These factors raise substantial doubt about the Company's ability to continue as a going concern.
	The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital through equity financing or related party loans.
	The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2012
Summary of Significant Accounting Policies [Text Block]	'
	Note 2. Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. The financial statements have been prepared under the guidelines of Accounting and Reporting by Development Stage Enterprises. A development stage enterprise is one in which planned principal operations have not commenced, or if its operations have commenced, there have been no significant revenues therefrom. As of December 31, 2012, we had not commenced our planned principal operations.
	Use of Estimates
	Preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued.
	Cash
	Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
	Fair Value of Financial Instruments
	Financial instruments, including cash, accounts payable and accrued liabilities, short-term loan and convertible note payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
	The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:
		Level 1 – quoted prices in active markets for identical assets or liabilities
		Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
		Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Level 1 input is used to measure cash. At December 31, 2012 there were no other assets or liabilities subject to additional disclosure.
	Revenue Recognition
	The Company recognizes revenue when a sale is made, the fee is fixed or determinable, collectability is probable, and no significant company obligations remain.
	Income Taxes
	The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.
	Research and Development Costs
	Research and development costs are expensed as incurred.
	Earnings per Share and Potentially Dilutive Securities
	Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 16,530,000 outstanding warrants and debt convertible into 1,200,000 common shares were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses. Common stock issuable is considered outstanding as of the original approval date for purposes of earnings per share computations.
	Share-Based Compensation
	The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes option-pricing model.
	The Company accounts for stock-based compensation under "Share-Based Payment," which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes option-pricing model.
	The Company accounts for stock compensation arrangements with non-employees in accordance with FASB Codification 505 – 50 “Equity-Based Payments to Non-Employees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes valuation model and the compensation charges are amortized over the vesting period.
	Related Party Transactions
	A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
	Recent Accounting Pronouncements
	The company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on the financial position or results of operations.

Accounts_Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2012
Accounts Receivable [Text Block]	'
	Note 3. Accounts Receivable
	The accounts receivable is refundable sales tax paid on purchases.

Short_Term_Loan

Short Term Loan	12 Months Ended
	Dec. 31, 2012
Short Term Loan [Text Block]	'
	Note 4. Short Term Loan
	The short term loan is unsecured, non-interest bearing and is payable on demand.

Convertible_Note_Payable

Convertible Note Payable	12 Months Ended
	Dec. 31, 2012
Convertible Note Payable [Text Block]	'
	Note 5. Convertible Note Payable
	On July 1, 2007, the Company executed a loan agreement under which the Company issued to a corporation an 8% convertible promissory note in exchange for $300,000. The note holder has the right to demand payment of outstanding principal and interest at any time with a 30 -day grace period. The note is due and payable no later than June 30, 2012, and is convertible into shares of the Company's common stock at $0.25 per share. No beneficial conversion feature was applicable to this convertible note. During the year ended December 31, 2011, the note holder demanded the repayment of the loan in cash. The Company negotiated with the note holder who accepted 9 million common shares of the Company as consideration for the settlement of the loan. On January 26, 2011, the Company issued 9 million shares at $0.07 per share to settle the convertible note. The fair value of the 9 million shares issued exceeds the loan principal by $330,000, which was recorded as loss on settlement of loan.
	On July 1, 2011, the Company executed a loan agreement under which the Company issued to a corporation an 8% convertible promissory note in exchange for $300,000. The note holder has the right to demand payment of outstanding principal and interest at any time with a 30 -day grace period. The note is due and payable no later than June 30, 2016, and is convertible into shares of the Company's common stock at $0.025 per share. No beneficial conversion feature was applicable to this convertible note.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2012
Income Taxes [Text Block]	'
	Note 6. Income Taxes
	The Company is liable for taxes in the United States. As of December 31, 2012, the Company did not have any income for tax purposes and therefore, no tax liability or expense has been recorded in these financial statements.
	The Company has tax losses of approximately $25,000,000 to reduce future taxable income. The tax losses expire in years starting from 2028.
	The deferred tax asset associated with the tax loss carry forward is approximately $8,500,000 ($8,500,000 for 2011). The Company has provided a full valuation allowance against the deferred tax asset since it is more likely than not that the asset will not be realized. The difference between the Company's statutory income tax rate of ( 34%) and its effective rate of zero is primarily attributable to the valuation allowance provided on deferred taxes arising from net operating loss carryforwards.

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2012
Share-Based Compensation [Text Block]	'
	Note 7. Share-Based Compensation
	In 2003, the Company adopted its 2003 and 2004 Stock Incentive Plans. Each plan provides for the issuance of incentive and non-qualified shares of the Company's stock to officers, directors, employees, and non-employees. The Board of Directors determines the terms of the shares or options to be granted, including the number of shares or options, the exercise price, and the vesting schedule, if applicable. In 2011 and 2012, the Company issued common shares from both plans to non-employee consultants for services rendered as follows:
		Number		Value
	2011	of Shares		per Share		Total
	March	550,000	$	0.06	$	33,000
	June	250,000		0.03		7,500
	July	200,000		0.03		6,000
	September	500,000		0.03		15,000
	October	750,000		0.03		22,500
	December	20,400,000		0.02		408,000
	Total, December 31, 2011	22,650,000			$	492,000
		Number of		Value per Share
	2012	Shares
	Total, December 31, 2012	$nil

Stock_Options

Stock Options	12 Months Ended
	Dec. 31, 2012
Stock Options [Text Block]	'
	Note 8. Stock Options
	Stock option transactions are summarized as follows:
						Weighted			Aggregate
			Number of			Average Exercise			Intrinsic
			Options			Price			Value
	Balance, December 31, 2010 and 2011		250,000		$	0.2		$	-
	Expired, April 2012		(250,000	)	$	(0.20	)
	Outstanding and exercisable at December 31, 2012		-		$	-		$	-
	Weighted average fair value of options granted during the year	$	Ni l
	At December 31, 2012, there were no stock options outstanding.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2012
Warrants [Text Block]	'
	Note 9. Warrants
	Warrant transactions are summarized as follows:
					Weighted
		Number of			Average Exercise
		Warrants			Price
	Balance, December 31, 2010	11,080,000		$	0.34
	Issued	-			-
	Expired/Cancelled	(6,800,000	)		0.32
	Balance, December 31, 2011	4,280,000			0.37
	Issued	15,000,000			0.03
	Expired/Cancelled	(2,750,000	)		0.5
	Balance, December 31, 2012	16,530,000		$	0.04
	Exercisable at December 31, 2012	16,530,000		$	0.04
	At December 31, 2012, the following warrants were outstanding:
	Number of Warrants		Exercise price			Expiry Date
	1,530,000	$	0.15			9-Feb-13
	15,000,000	$	0.03			15-Jan-14
	16,530,000
	During 2012, the Company issued 15,000,000 (2011 – nil) warrants to purchase common stock at an exercise price of $0.03 (2011 - $nil) per share pursuant to the terms of private placements closed that were issued to settle short-term loans during the year.

Stockholders_Deficiency

Stockholders Deficiency	12 Months Ended
	Dec. 31, 2012
Stockholders Deficiency [Text Block]	'
	Note 10. Stockholders’ Deficiency
	The Company is authorized to issue 200,000,000 shares of $0.0000053 par value common stock. During 2011 the company increased its authorized shares from 100,000,000 to 200,000,000. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of December 31, 2012.
	During the year ended December 31, 2012, the Company:
		1	Issued 15,000,000 common shares in private placements for total proceeds of $150,000, of which $25,000 settled a portion of the short-term loan.
	During the year ended December 31, 2011, the Company
		2	Issued 750,000 common shares in private placements for total proceeds of $75,000.
		3	Issued 9,000,000 common shares to settle the convertible debt of $630,000.
		4	Issued 26,050,000 shares for services with total valuation of $560,000, of which $545,000 was recorded in consulting and research and development expenses and $15,000 in prepaid expenses which will be amortized through year 2012.

Subsequent_Event

Subsequent Event	12 Months Ended
	Dec. 31, 2012
Subsequent Event [Text Block]	'
	Note 11. Subsequent Events
	Subsequent to the year ended December 31, 2012, the Company issued 35,850,000 common shares.
		1	Issued 7,300,000 common shares in private placements to settle a portion of the short-term loan of $73,000.
		2	Issued 27,550,000 common shares for services with a total valuation of $275,500.
		3	Issued 1,000,000 common shares in private placements for total proceeds of $10,000.
	The Company entered into an agreement to sell the exclusive rights for the application of the AAGP molecule. The total purchase price for the exclusive rights to the application is $2,500,000 to be paid as follows:
	$25,000 cash deposit (received);
	$25,000 paid by cash on or before April 22, 2014 as a balance of the transaction deposit;
	Six monthly payments of $25,000 on or before May 22, June 22, July 22, August 22, August 22, September 22 and October 22, 2014;
	$2,300,000 paid by the issuance of 3,500,000 restricted shares of the buyer as payment of the outstanding balance. These shares can be redeemed by a cash payment at any time within the first 6 months of the effective date of this agreement.
	Once the Company has received $2,500,000 in total through payment, sale of the shares and through the redemption of the shares, any surplus shares will be returned to the buyer. In the event that the total payment has not totaled $2,500,000, the buyer will pay the difference to the Company by wire transfer no later than 13 months after the effective date of this agreement.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2012
Use of Estimates [Policy Text Block]	'
	Use of Estimates
	Preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued.
Cash [Policy Text Block]	'
	Cash
	Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
Fair Value of Financial Instruments [Policy Text Block]	'
	Fair Value of Financial Instruments
	Financial instruments, including cash, accounts payable and accrued liabilities, short-term loan and convertible note payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
	The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:
		Level 1 – quoted prices in active markets for identical assets or liabilities
		Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
		Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Level 1 input is used to measure cash. At December 31, 2012 there were no other assets or liabilities subject to additional disclosure.
Revenue Recognition [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue when a sale is made, the fee is fixed or determinable, collectability is probable, and no significant company obligations remain.
Income Taxes [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.
Research and Development Costs [Policy Text Block]	'
	Research and Development Costs
	Research and development costs are expensed as incurred.
Earnings per Share and Potentially Dilutive Securities [Policy Text Block]	'
	Earnings per Share and Potentially Dilutive Securities
	Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 16,530,000 outstanding warrants and debt convertible into 1,200,000 common shares were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses. Common stock issuable is considered outstanding as of the original approval date for purposes of earnings per share computations.
Share-Based Compensation [Policy Text Block]	'
	Share-Based Compensation
	The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes option-pricing model.
	The Company accounts for stock-based compensation under "Share-Based Payment," which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes option-pricing model.
	The Company accounts for stock compensation arrangements with non-employees in accordance with FASB Codification 505 – 50 “Equity-Based Payments to Non-Employees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes valuation model and the compensation charges are amortized over the vesting period.
Related Party Transactions [Policy Text Block]	'
	Related Party Transactions
	A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Recent Accounting Pronouncements [Policy Text Block]	'
	Recent Accounting Pronouncements
	The company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on the financial position or results of operations.

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2012			Dec. 31, 2011
Schedule of Stock Incentive Plan, Issuances [Table Text Block]	'			'
		Number of	Value per Share		Number		Value
	2012	Shares		2011	of Shares		per Share		Total
	Total, December 31, 2012	$nil
				March	550,000	$	0.06	$	33,000
				June	250,000		0.03		7,500
				July	200,000		0.03		6,000
				September	500,000		0.03		15,000
				October	750,000		0.03		22,500
				December	20,400,000		0.02		408,000
				Total, December 31, 2011	22,650,000			$	492,000

Stock_Options_Tables

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2012
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
						Weighted			Aggregate
			Number of			Average Exercise			Intrinsic
			Options			Price			Value
	Balance, December 31, 2010 and 2011		250,000		$	0.2		$	-
	Expired, April 2012		(250,000	)	$	(0.20	)
	Outstanding and exercisable at December 31, 2012		-		$	-		$	-
	Weighted average fair value of options granted during the year	$	Ni l

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Dec. 31, 2012
Schedule of Warrant Activity [Table Text Block]	'
					Weighted
		Number of			Average Exercise
		Warrants			Price
	Balance, December 31, 2010	11,080,000		$	0.34
	Issued	-			-
	Expired/Cancelled	(6,800,000	)		0.32
	Balance, December 31, 2011	4,280,000			0.37
	Issued	15,000,000			0.03
	Expired/Cancelled	(2,750,000	)		0.5
	Balance, December 31, 2012	16,530,000		$	0.04
	Exercisable at December 31, 2012	16,530,000		$	0.04
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	Number of Warrants		Exercise price			Expiry Date
	1,530,000	$	0.15			9-Feb-13
	15,000,000	$	0.03			15-Jan-14
	16,530,000

Basis_of_Presentation_Going_Co1

Basis of Presentation Going Concern Uncertainties (Narrative) (Details)	12 Months Ended
	Dec. 31, 2003
Stock issued to shareholders of BioKinetix	16,000,000

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2012
Warrant [Member]	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	16,530,000
Convertible Debt Securities [Member]	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	1,200,000

Convertible_Note_Payable_Narra

Convertible Note Payable (Narrative) (Details) (USD $)	12 Months Ended		156 Months Ended	1 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Jan. 26, 2011	Jul. 01, 2011	Jul. 01, 2007
				Convertible Debt [Member]	Convertible Debt [Member]	Convertible Debt [Member]
Convertible debt interest rate	'	'	'	'	8.00%	8.00%
Convertible notes payable	'	'	'	'	$300,000	$300,000
Grace period	'	'	'	'	'30 days	'30 days
Convertible debt conversion price	'	'	'	$0.07	$0.03	$0.25
Stock Issued During Period, Shares, Conversion of Convertible Note	'	9,000,000	'	9,000,000	'	'
Loss on settlement of debt	$0	($330,000)	($330,000)	($330,000)	'	'

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Tax losses to reduce future taxable income	$25,000,000	'
Deferred tax asset, tax loss carry forward	$8,500,000	$8,500,000
Statutory income tax rate	34.00%	'

Warrants_Narrative_Details

Warrants (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Warrants issued during period	15,000,000	0
Class of warrants or rights expired exercise price	$0.03	$0

Stockholders_Deficiency_Narrat

Stockholders Deficiency (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Common Stock, Shares Authorized	200,000,000	200,000,000	100,000,000
Common Stock, Par or Stated Value Per Share	$0.00	$0.00	'
Issuance of common stock from Private Placement (Shares)	15,000,000	'	'
Issuable common stock from Private Placement (Shares)	'	750,000	'
Proceeds from Issuance of Private Placement	$150,000	$75,000	'
Shares issued to settle debt	25,000	'	'
Stock Issued During Period, Shares, Conversion of Convertible Note	'	9,000,000	'
Issuance of common stock to settle convertible debt	'	630,000	'
Issuance of common stock for services (Shares)	'	26,050,000	'
Issuance of common stock for services	200,000,000	560,000	'
Consulting and Research and Development Expenses [Member]	'	'	'
Issuance of common stock for services	'	545,000	'
Prepaid Expenses [Member]	'	'	'
Issuance of common stock for services	'	$15,000	'

Subsequent_Event_Narrative_Det

Subsequent Event (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Issuance of common stock for services (Shares)	'	26,050,000
Issuance of common stock for services	$200,000,000	$560,000
Prepaid Expenses [Member]	'	'
Issuance of common stock for services	'	15,000
Subsequent Event [Member]	'	'
Subseqent event, shares issued	35,850,000	'
Issuance of common stock for services (Shares)	27,550,000	'
Issuance of common stock for services	275,500	'
Proceeds from rights agreement	2,500,000	'
Cash deposit received	25,000	'
Cash to be received	25,000	'
Monthly payments	25,000	'
Restricted shares received as payment,, shares	3,500,000	'
Restriced shares, value	2,300,000	'
Subsequent Event [Member] | Private Placement [Member]	'	'
Common shares issued	1,000,000	'
Common shares issued, value	10,000	'
Subsequent Event [Member] | Short-term loan [Member] | Private Placement [Member]	'	'
Common shares issued	7,300,000	'
Common shares issued, value	$73,000	'

Schedule_of_Stock_Incentive_Pl

Schedule of Stock Incentive Plan, Issuances (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Number of Shares	0	22,650,000
Total	'	$492,000
March [Member]	'	'
Number of Shares	'	550,000
Value per Share	'	$0.06
Total	'	33,000
June [Member]	'	'
Number of Shares	'	250,000
Value per Share	'	$0.03
Total	'	7,500
July [Member]	'	'
Number of Shares	'	200,000
Value per Share	'	$0.03
Total	'	6,000
September [Member]	'	'
Number of Shares	'	500,000
Value per Share	'	$0.03
Total	'	15,000
October [Member]	'	'
Number of Shares	'	750,000
Value per Share	'	$0.03
Total	'	22,500
December [Member]	'	'
Number of Shares	'	20,400,000
Value per Share	'	$0.02
Total	'	$408,000

Schedule_of_Sharebased_Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details) (USD $)	12 Months Ended	24 Months Ended
	Dec. 31, 2012	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period	'	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	'	$0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value, Beginning of Period	'	$0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	'	-250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	'	($0.20)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, End of Period	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, End of Period	$0	$0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value, End of Period	$0	$0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	0	'

Schedule_of_Warrant_Activity_D

Schedule of Warrant Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Warrants beginning balance	4,280,000	11,080,000
Weighted average exercise price beginning balance	$0.37	$0.34
Warrants issued during period	15,000,000	0
Weighted average exercise price warrants issued	$0.03	$0
Warrants expired/cancelled	-2,750,000	-6,800,000
Weighted average exercise price warrants expired/cancelled	$0.50	$0.32
Warrants ending balance	16,530,000	4,280,000
Weighed average exercise price ending balance	$0.04	$0.37
Exercisable at the end of period	16,530,000	'
Weighted average exercise price at the end of period	$0.04	'

Schedule_of_Stockholders_Equit

Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Number of Warrants	16,530,000	4,280,000	11,080,000
Warrants at $0.15 expiring February 9, 2013 [Member]	'	'	'
Number of Warrants	1,530,000	'	'
Warrant Exercise Price	0.15	'	'
Warrants at $0.03 expiring January 15, 2014 [Member]	'	'	'
Number of Warrants	15,000,000	'	'
Warrant Exercise Price	0.03	'	'